Olink's Proximity Extension Assay (PEA™) and mass spectrometry (MS) are powerful, complementary technologies for proteomic studies. PEA offers high specificity and sensitivity for low-abundance proteins, while liquid chromatography mass spectrometry (LC-MS) provides unbiased protein coverage and detects isoforms and modifications. Together, they expand proteome coverage and accelerate biomarker discovery & validation Dive into this comprehensive white paper to uncover a detailed comparison of PEA and LC-MS, and explore how this groundbreaking synergy has powered success stories in published research. https://bit.ly/3Y4fhmG
Om oss
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base. For more information visit www.olink.com
- Webbplats
-
http://www.olink.com
Extern länk för Olink Proteomics
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 201–500 anställda
- Huvudkontor
- Uppsala
- Typ
- Privatägt företag
- Grundat
- 2004
- Specialistområden
- Targeted protein biomarker discovery och Precision proteomics
Adresser
-
Primär
Uppsala Science Park
Uppsala, SE-75183, SE
-
65 Grove street (ground floor)
Watertown, MA 02472, US
Anställda på Olink Proteomics
-
Michael B. Gonzales, PhD
Vice President of Global Marketing, Olink Proteomics
-
Johan Montén
Makes strategies work, specifically for IT-related transformations. Leading change with top management.
-
Paula de Galan
Technical Sales Specialist • Connect & Communicate • Life Sciences • Event Management • Solution oriented
-
Henrik Tommerup
OLINK | drug dev. proteomics & reverse translation
Uppdateringar
-
Olink Proteomics omdelade detta
Exciting Announcement: Olink Proteomics at IMMUNOCON 2024! We’re thrilled to announce Olink’s participation at IMMUNOCON 2024, happening from October 17-20 at the iconic J.N. Tata Auditorium Complex, Indian Institute of Science, Bengaluru. Join us at Booth No. 7 to explore how protein biomarker screening can advance the study of disease-specific biomarkers in immunology and beyond. Don’t miss the chance to discover the latest breakthroughs in proteomics and proteogenomics. We look forward to seeing you there and discussing the future of biomarker research! #OlinkProteomics #IMMUNOCON2024 #Proteomics #Proteogenomics #iisc #icmr #dgicmr #dcgi #indianimmunologysociety #immunology #immunocon51
-
We're #hiring a new Development Engineer - Systems in Uppsala, Uppsala County. Apply today or share this post with your network.
-
We're #hiring a new Account Development Representative - South Europe in Madrid, Community of Madrid. Apply today or share this post with your network.
-
Learn how leading proteomics scientists combine Proximity Extension Assay (PEA) with mass spectrometry to achieve extended coverage of the proteome. Listen to this insightful podcast featuring Dr. Stephanie Hauck and Dr. Gabi Kastenmüller from Helmholtz Munich, as they delve into the emerging new era of proteomics, the great potential value of studying the plasma proteome and the challenges involved. https://hubs.la/Q02RsGm10 #Olink
-
We're #hiring a new Data Scientist in Toronto, Ontario. Apply today or share this post with your network.
-
This #weeklyread describes how multiple Olink® Target 96 panels were used to gain pharmacodynamic insights in a clinical trial where psoriasis patients were treated with the tyrosine kinase inhibitor, deucravacitinib. In addition to providing valuable information regarding the proteins and pathways involved in deucravacitinib therapy, this study also demonstrated the utility of circulating biomarkers to investigate the relevant biology from localized disease sites such as psoriasis lesions. Key highlights • Serum biomarkers associated with the IL-23/Th17 pathway were upregulated in psoriasis patients vs controls, consistent with the Th17 phenotype of psoriatic disease. • Deucravacitinib treatment significantly reduced several of these serum biomarkers in a time- and dose-dependent manner. • Biomarker expression was also correlated with psoriasis disease activity measures, both at baseline and in response to treatment. • The serum proteomics data was highly consistent with mRNA expression data measured in lesional skin in the primary trial. The authors concluded, “This exploratory biomarker analysis demonstrated that biomarkers derived from inflamed psoriatic lesions can be detected in the blood of patients with psoriasis. These biomarkers reflect the level of disease activity and changes resulting from pharmacological intervention with drugs”. Read the article: https://bit.ly/3BAUZti #olink #proteomics #biomarkers #drugdevelopment
-
We're #hiring a new Data Scientist in Uppsala, Uppsala County. Apply today or share this post with your network.
-
Learn how PEA™ technology addresses key challenges in proteomics at our lunch symposium at HUPO on October 22nd. Our speakers will explore the evolution of the UK Biobank and its profound impact on the future of healthcare. Discover how Olink’s PEA™ technology is uniquely suited to support population-scale proteomics studies, enhancing our understanding of human biology and driving research from discovery to clinical utility. Secure your seat here: https://bit.ly/47YwG4E #HUPO2024 #Proteomics #UKBiobank #Olink
-
We are delighted that this year's Nobel Prize for Chemistry has been jointly awarded to three outstanding scientists working in the fields of protein structure prediction and computational protein design. The award is a reaffirmation of the vital role that proteins play in human biology, connecting the genome to phenotype, driving most biological processes, and providing the interventional targets for most current drugs. Olink has a long commitment to innovation and an established track record of success in protein biomarker research, and we wholeheartedly congratulate this year’s winners of the Nobel Prize for Chemistry for this well-deserved recognition of their outstanding contributions to protein science. https://bit.ly/4gYiMDt
The Nobel Prize on LinkedIn: BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award… | 252 comments
linkedin.com
Liknande sidor
Finansiering
Senaste finansieringsrunda
Eget kapital117 000 000,00 US$